Clinical Trial Update: Phase 2a Study of Safety and Tolerability of SPN-810 in Children With ADHD and Persistent Serious Conduct Problems [Phase 2]

View source ↗

Summary

This clinical-trial update reports the completion of a Phase 2a study evaluating the safety and tolerability of SPN-810 in children with attention deficit hyper…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Attention Deficit Hyperactivity Disorder
• Conduct Disorder

Drugs mentioned

• SPN-810 (viloxazine extended-release)

Snippet

Sponsor: Supernus Pharmaceuticals, Inc. | Conditions: Attention Deficit Disorder With Hyperactivity, Conduct Disorder | Phase 2 | Status: COMPLETED | Results posted: 2025-09-16